Cipher Pharmaceuticals Inc

OTCQX International:CPHRFUnited StatesView on Canadian Exchange

dilutive 0.16 0.14 0.43 0.38
Consolidated statements of income and comprehensive income
Three monthsended September Nine monthsended September 30, 30, (IN THOUSANDS 2024 2023 2024 2023 OF U.S. DOLLARS, except for per $ $ $ $ share amounts) Revenue Licensing revenue 1,055 3,090 5,273 6,936 Product revenue 9,315 2,978 16,268 9,306 Net revenue 10,370 6,068 21,541 16,242 Operating expenses Cost of products sold 1,970 1,076 4,131 3,114 Research and development -- 10 -- 110 Depreciation and amortization 1,925 269 2,506 954 Selling, general and administrative 6,182 1,690 9,251 4,400 Total operating expenses 10,077 3,045 15,888 8,578 Other (income) expenses Interest expense (income) 292 (533) (874) (1,315) Unrealized foreign exchange (gain) loss (325) 434 718 (21) Total other (income) expenses (33) (99) (156) (1,336) Income before income taxes 326 3,122 5,809 9,000 Current income tax expense -- 116 -- 328 Deferred income tax expense (recovery) 43 (4,025) (2,392) (4,056) Total income tax expense (recovery) 43 (3,909) (2,392) (3,728) Net income and comprehensive income for the period 283 7,031 8,201 12,728 Income per share Basic 0.01 0.28 0.34 0.50 Diluted 0.01 0.27 0.33 0.50